APAnthony Philippakis

Anthony Philippakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anthony Philippakis has a total of 371 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unsupervised deep learning of electrocardiograms enables scalable human disease profiling

    by Sam F. Friedman, Shaan Khurshid, Rachael A. Venn, Xin Wang, Nate Diamant, Paolo Di Achille, Lu-Chen Weng, Seung Hoan Choi, Christopher Reeder, James P. Pirruccello, et al.

    The 12-lead electrocardiogram (ECG) is inexpensive and widely available. Whether conditions across the human disease landscape can be detected using the ECG is unclear. We developed a deep learning denoising autoencoder and systematically evaluated associations between ECG encodings and ~1,600 Phecode-based diseases in three datasets separate from model development, and meta-analyzed the results. The latent space ECG model identified associations with 645 prevalent and 606 incident Phecodes. Associations were most enriched in the circulatory (n = 140, 82% of category-specific Phecodes), respiratory (n = 53, 62%) and endocrine/metabolic (n = 73, 45%) categories, with additional associations across the phenome. The strongest ECG association was with hypertension (p < 2.2×10-308). The ECG latent space model demonstrated more associations than models using standard ECG intervals, and offered favorable discrimination of prevalent disease compared to models comprising age, sex, and race. We further demonstrate how latent space models can be used to generate disease-specific ECG waveforms and facilitate individual disease profiling.


  • Noninvasive assessment of organ-specific and shared pathways in multi-organ fibrosis using T1 mapping

    by Victor Nauffal, Marcus D. R. Klarqvist, Matthew C. Hill, Danielle F. Pace, Paolo Di Achille, Seung Hoan Choi, Joel T. Rämö, James P. Pirruccello, Pulkit Singh, Shinwan Kany, et al.

    Fibrotic diseases affect multiple organs and are associated with morbidity and mortality. To examine organ-specific and shared biologic mechanisms that underlie fibrosis in different organs, we developed machine learning models to quantify T1 time, a marker of interstitial fibrosis, in the liver, pancreas, heart and kidney among 43,881 UK Biobank participants who underwent magnetic resonance imaging. In phenome-wide association analyses, we demonstrate the association of increased organ-specific T1 time, reflecting increased interstitial fibrosis, with prevalent diseases across multiple organ systems. In genome-wide association analyses, we identified 27, 18, 11 and 10 independent genetic loci associated with liver, pancreas, myocardial and renal cortex T1 time, respectively. There was a modest genetic correlation between the examined organs. Several loci overlapped across the examined organs implicating genes involved in a myriad of biologic pathways including metal ion transport (SLC39A8, HFE and TMPRSS6), glucose metabolism (PCK2), blood group antigens (ABO and FUT2), immune function (BANK1 and PPP3CA), inflammation (NFKB1) and mitosis (CENPE). Finally, we found that an increasing number of organs with T1 time falling in the top quintile was associated with increased mortality in the population. Individuals with a high burden of fibrosis in ≥3 organs had a 3-fold increase in mortality compared to those with a low burden of fibrosis across all examined organs in multivariable-adjusted analysis (hazard ratio = 3.31, 95% confidence interval 1.77–6.19; P = 1.78 × 10−4). By leveraging machine learning to quantify T1 time across multiple organs at scale, we uncovered new organ-specific and shared biologic pathways underlying fibrosis that may provide therapeutic targets.


  • Open Access

    Deep learning of left atrial structure and function provides link to atrial fibrillation risk

    by James P. Pirruccello, Paolo Di Achille, Seung Hoan Choi, Joel T. Rämö, Shaan Khurshid, Mahan Nekoui, Sean J. Jurgens, Victor Nauffal, Shinwan Kany, Finn Gen, et al.

    Increased left atrial volume and decreased left atrial function have long been associated with atrial fibrillation. The availability of large-scale cardiac magnetic resonance imaging data paired with genetic data provides a unique opportunity to assess the genetic contributions to left atrial structure and function, and understand their relationship with risk for atrial fibrillation. Here, we use deep learning and surface reconstruction models to measure left atrial minimum volume, maximum volume, stroke volume, and emptying fraction in 40,558 UK Biobank participants. In a genome-wide association study of 35,049 participants without pre-existing cardiovascular disease, we identify 20 common genetic loci associated with left atrial structure and function. We find that polygenic contributions to increased left atrial volume are associated with atrial fibrillation and its downstream consequences, including stroke. Through Mendelian randomization, we find evidence supporting a causal role for left atrial enlargement and dysfunction on atrial fibrillation risk.


  • Open Access

    Latent Space Explorer: Visual Analytics for Multimodal Latent Space Exploration

    by Bum Chul Kwon, Samuel Friedman, Kai Xu, Steven A Lubitz, Anthony Philippakis, Puneet Batra, Patrick T Ellinor, Kenney Ng

    Machine learning models built on training data with multiple modalities can reveal new insights that are not accessible through unimodal datasets. For example, cardiac magnetic resonance images (MRIs) and electrocardiograms (ECGs) are both known to capture useful information about subjects' cardiovascular health status. A multimodal machine learning model trained from large datasets can potentially predict the onset of heart-related diseases and provide novel medical insights about the cardiovascular system. Despite the potential benefits, it is difficult for medical experts to explore multimodal representation models without visual aids and to test the predictive performance of the models on various subpopulations. To address the challenges, we developed a visual analytics system called Latent Space Explorer. Latent Space Explorer provides interactive visualizations that enable users to explore the multimodal representation of subjects, define subgroups of interest, interactively decode data with different modalities with the selected subjects, and inspect the accuracy of the embedding in downstream prediction tasks. A user study was conducted with medical experts and their feedback provided useful insights into how Latent Space Explorer can help their analysis and possible new direction for further development in the medical domain.

  • Open Access

    Generating Drug Repurposing Hypotheses through the Combination of Disease-Specific Hypergraphs

    by Ayush Jain, Marie Laure-Charpignon, Irene Y. Chen, Anthony Philippakis, Ahmed Alaa

    The drug development pipeline for a new compound can last 10-20 years and cost over 10 billion. Drug repurposing offers a more time- and cost-effective alternative. Computational approaches based on biomedical knowledge graph representations have recently yielded new drug repurposing hypotheses. In this study, we present a novel, disease-specific hypergraph representation learning technique to derive contextual embeddings of biological pathways of various lengths but that all start at any given drug and all end at the disease of interest. Further, we extend this method to multi-disease hypergraphs. To determine the repurposing potential of each of the 1,522 drugs, we derive drug-specific distributions of cosine similarity values and ultimately consider the median for ranking. Cosine similarity values are computed between (1) all biological pathways starting at the considered drug and ending at the disease of interest and (2) all biological pathways starting at drugs currently prescribed against that disease and ending at the disease of interest. We illustrate our approach with Alzheimer's disease (AD) and two of its risk factors: hypertension (HTN) and type 2 diabetes (T2D). We compare each drug's rank across four hypergraph settings (single- or multi-disease): AD only, AD + HTN, AD + T2D, and AD + HTN + T2D. Notably, our framework led to the identification of two promising drugs whose repurposing potential was significantly higher in hypergraphs combining two diseases: dapagliflozin (antidiabetic; moved up, from top 32$\%$ to top 7$\%$, across all considered drugs) and debrisoquine (antihypertensive; moved up, from top 76$\%$ to top 23$\%$). Our approach serves as a hypothesis generation tool, to be paired with a validation pipeline relying on laboratory experiments and semi-automated parsing of the biomedical literature.

  • Abstract 13880: Natural Language Processing for Adjudication of Heart Failure Hospitalizations in a Multi-Center Clinical Trial

    by Jonathan Cunningham, Pulkit Singh, Christopher Reeder, Brian Claggett, Pablo-Miki Marti Castellote, Emily Lau, Shaan Khurshid, Puneet Batra, Steven Lubitz, Mahnaz Maddah, et al.


  • Open Access

    Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course

    by Sarah M. Urbut, So Mi Jemma Cho, Kaavya Paruchuri, Buu Truong, Sara Haidermota, Gina M. Peloso, Whitney Hornsby, Anthony Philippakis, Akl C. Fahed, Pradeep Natarajan

    Structured Importance: Earlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. Understanding the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction. Objective: To assess the time-varying significance of genomic and clinical risk factors in CAD risk estimation across various age groups. Design, Setting, and Participants: A longitudinal study was performed using data from two cohort studies: the Framingham Offspring Study (FOS) with 3,588 participants aged 19-57 years and the UK Biobank (UKB) with 327,837 participants aged 40-70 years. A total of 134,765 and 3,831,734 person-time years were observed in FOS and UKB, respectively. Main Outcomes and Measures: Hazard ratios (HR) for CAD were calculated for polygenic risk scores (PRS) and clinical risk factors at each age of enrollment. The relative importance of PRS and Pooled Cohort Equations (PCE) in predicting CAD events was also evaluated by age groups. Results: The importance of CAD PRS diminished over the life course, with an HR of 3.58 (95% CI 1.39-9.19) at age 19 in FOS and an HR of 1.51 (95% CI 1.48-1.54) by age 70 in UKB. Clinical risk factors exhibited similar age-dependent trends. PRS significantly outperformed PCE in identifying subsequent CAD events in the 40-45-year age group, with 3.2-fold more appropriately identified events. The mean age of CAD events occurred 1.8 years earlier for those at high genomic risk but 9.6 years later for those at high clinical risk (p<0.001). Overall, adding PRS improved the area under the receiving operating curve of the PCE by an average of +5.1% (95% CI 4.9-5.2%) across all age groups; among individuals <55 years, PRS augmented the AUC-ROC of the PCE by 6.5% (95% CI 5.5-7.5%, p<0.001). Conclusions and Relevance: Genomic and clinical risk factors for CAD display time-varying importance across the lifespan. The study underscores the added value of CAD PRS, particularly among individuals younger than 55 years, for enhancing early risk prediction and prevention strategies. Key Points Question: How do genomic and clinical risk factors contribute to coronary artery disease (CAD) risk across a broad age range? Findings: This longitudinal observational study across two cohorts found that both genomic and clinical risk factors exhibit age-dependent significance for CAD risk. Polygenic risk scores (PRS) are most informative for individuals younger than 55 years, improving the predictive accuracy of current risk equations for these individuals. Meaning: The study emphasizes the need to incorporate the dynamic effects of cardiovascular risk factors, particularly genomic risk, for more accurate early-life risk prediction and efficient CAD prevention strategies.


  • Open Access

    Demonstrating paths for unlocking the value of cloud genomics through cross cohort analysis

    by Nicole Deflaux, Margaret Sunitha Selvaraj, Henry Robert Condon, Kelsey Mayo, Sara Haidermota, Melissa A. Basford, Chris Lunt, Anthony A. Philippakis, Dan M. Roden, Joshua C. Denny, et al.

    Recently, large scale genomic projects such asAll of Usand the UK Biobank have introduced a new research paradigm where data are stored centrally in cloud-based Trusted Research Environments (TREs). To characterize the advantages and drawbacks of different TRE attributes in facilitating cross-cohort analysis, we conduct a Genome-Wide Association Study of standard lipid measures using two approaches: meta-analysis and pooled analysis. Comparison of full summary data from both approaches with an external study shows strong correlation of known loci with lipid levels (R2 ~ 83–97%). Importantly, 90 variants meet the significance threshold only in the meta-analysis and 64 variants are significant only in pooled analysis, with approximately 20% of variants in each of those groups being most prevalent in non-European, non-Asian ancestry individuals. These findings have important implications, as technical and policy choices lead to cross-cohort analyses generating similar, but not identical results, particularly for non-European ancestral populations.


  • Open Access

    Natural Language Processing for Adjudication of Heart Failure Hospitalizations in a Multi-Center Clinical Trial

    by Jonathan W. Cunningham, Pulkit Singh, Christopher Reeder, Brian Claggett, Pablo M. Marti-Castellote, Emily S. Lau, Shaan Khurshid, Puneet Batra, Steven A. Lubitz, Mahnaz Maddah, et al.

    Background: The gold standard for outcome adjudication in clinical trials is chart review by a physician clinical events committee (CEC), which requires substantial time and expertise. Automated adjudication by natural language processing (NLP) may offer a more resource-efficient alternative. We previously showed that the Community Care Cohort Project (C3PO) NLP model adjudicates heart failure (HF) hospitalizations accurately within one healthcare system. Methods: This study externally validated the C3PO NLP model against CEC adjudication in the INVESTED trial. INVESTED compared influenza vaccination formulations in 5260 patients with cardiovascular disease at 157 North American sites. A central CEC adjudicated the cause of hospitalizations from medical records. We applied the C3PO NLP model to medical records from 4060 INVESTED hospitalizations and evaluated agreement between the NLP and final consensus CEC HF adjudications. We then fine-tuned the C3PO NLP model (C3PO+INVESTED) and trained a de novo model using half the INVESTED hospitalizations, and evaluated these models in the other half. NLP performance was benchmarked to CEC reviewer inter-rater reproducibility. Results: 1074 hospitalizations (26%) were adjudicated as HF by the CEC. There was high agreement between the C3PO NLP and CEC HF adjudications (agreement 87%, kappa statistic 0.69). C3PO NLP model sensitivity was 94% and specificity was 84%. The fine-tuned C3PO and de novo NLP models demonstrated agreement of 93% and kappa of 0.82 and 0.83, respectively. CEC reviewer inter-rater reproducibility was 94% (kappa 0.85). Conclusion: Our NLP model developed within a single healthcare system accurately identified HF events relative to the gold-standard CEC in an external multi-center clinical trial. Fine-tuning the model improved agreement and approximated human reproducibility. NLP may improve the efficiency of future multi-center clinical trials by accurately identifying clinical events at scale.


  • Genetic Susceptibility to Atrial Fibrillation Identified via Deep Learning of 12-Lead Electrocardiograms

    by Xin Wang, Shaan Khurshid, Seung Hoan Choi, Samuel Friedman, Lu-Chen Weng, Christopher Reeder, James P. Pirruccello, Pulkit Singh, Emily S. Lau, Rachael Venn, et al.

    BACKGROUND:Artificial intelligence (AI) models applied to 12-lead ECG waveforms can predict atrial fibrillation (AF), a heritable and morbid arrhythmia. However, the factors forming the basis of risk predictions from AI models are usually not well understood. We hypothesized that there might be a genetic basis for an AI algorithm for predicting the 5-year risk of new-onset AF using 12-lead ECGs (ECG-AI)-based risk estimates. METHODS:We applied a validated ECG-AI model for predicting incident AF to ECGs from 39 986 UK Biobank participants without AF. We then performed a genome-wide association study (GWAS) of the predicted AF risk and compared it with an AF GWAS and a GWAS of risk estimates from a clinical variable model. RESULTS:In the ECG-AI GWAS, we identified 3 signals (P<5x10(-8)) at established AF susceptibility loci marked by the sarcomeric gene TTN and sodium channel genes SCN5A and SCN10A. We also identified 2 novel loci near the genes VGLL2 and EXT1. In contrast, the clinical variable model prediction GWAS indicated a different genetic profile. In genetic correlation analysis, the prediction from the ECG-AI model was estimated to have a higher correlation with AF than that from the clinical variable model. CONCLUSIONS:Predicted AF risk from an ECG-AI model is influenced by genetic variation implicating sarcomeric, ion channel and body height pathways. ECG-AI models may identify individuals at risk for disease via specific biological pathways.